1. INTENDED USE

Reagent 22/274 is prepared from IVR-215 (H1N1), a reassortant of A/Victoria/2570/2019 (H1N1) and A/Texas/1/77 (H3N2), which was processed in 250µl volumes as liquid stock. The derivation and known passage history of IVR-215 are attached.

2. CAUTION

This preparation is not for administration to humans or animals in the human food chain

The material is not of human or bovine origin.

As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures should include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

3. UNITAGE

No unitage is assigned to this material

4. CONTENTS

Country of origin of biological material: United Kingdom.

Each ampoule contains 250µl (nominal) of infectious influenza virus as allantoic fluid from SPF embryonated hen’s eggs.

5. STORAGE

Store in the dark at -70°C or below

Please note because of the inherent stability of lyophilized material, NIBSC may ship these materials at ambient temperature.

6. DIRECTIONS FOR OPENING

Vials have a screw cap; an internal stopper may also be present. The cap should be removed by turning anti-clockwise. Care should be taken to prevent loss of the contents. Please note: If a stopper is present on removal of the cap, the stopper should remain in the vial or be removed with the cap.

7. USE OF MATERIAL

Ready to use

8. STABILITY

Reference Materials should be stored on receipt as indicated on the label.

NIBSC follows the policy of WHO with respect to its reference materials.

9. REFERENCES

NA

10. ACKNOWLEDGEMENTS

NA

11. FURTHER INFORMATION

Further information can be obtained as follows:

This material: enquiries@nibsc.org

WHO Biological Standards:
http://www.who.int/biologicals/en/

JCTLM Higher order reference materials:
http://www.bipm.org/en/committees/jc/jctlm/

Derivation of International Units:
http://www.nibsc.org/standardisation/international_standards.aspx

Ordering standards from NIBSC:
http://www.nibsc.org/products/ordering.aspx

NIBSC Terms & Conditions:
http://www.nibsc.org/terms_and_conditions.aspx

12. CUSTOMER FEEDBACK

Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to enquiries@nibsc.org

13. CITATION

In all publications, including data sheets, in which this material is referenced, it is important that the preparation’s title, its status, the NIBSC code number, and the name and address of NIBSC are cited and cited correctly.

14. MATERIAL SAFETY SHEET

Classification in accordance with Directive 2000/54/EC, Regulation (EC) No 1272/2008: Not applicable or not classified

<table>
<thead>
<tr>
<th>Physical and Chemical properties</th>
<th>Toxicological properties</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance: Clear liquid</td>
<td>Effects of inhalation: Likelihood of influenza virus infection</td>
</tr>
<tr>
<td>Corrosive: No</td>
<td>Effects of ingestion: Not established, avoid ingestion</td>
</tr>
<tr>
<td>Stable: Yes</td>
<td>Effects of skin absorption: Not established, avoid contact with skin</td>
</tr>
<tr>
<td>Hygroscopic: No</td>
<td>Handling: See caution, Section 2</td>
</tr>
<tr>
<td>Oxidising: No</td>
<td></td>
</tr>
<tr>
<td>Flammable: No</td>
<td></td>
</tr>
<tr>
<td>Irritant: No</td>
<td></td>
</tr>
<tr>
<td>Other (specify): Live influenza virus</td>
<td></td>
</tr>
</tbody>
</table>

Suggested First Aid

Inhalation: Seek medical advice

Ingestion: Seek medical advice

Contact with eyes: Wash with copious amounts of water. Seek medical advice

Contact with skin: Wash thoroughly with water.
**Action on Spillage and Method of Disposal**

Spillage of contents should be taken up with absorbent material wetted with an appropriate virucidal agent. Rinse area with an appropriate virucidal agent followed by water. Absorbent materials used to treat spillage should be treated as biologically hazardous waste.

<table>
<thead>
<tr>
<th>Cumulative number of passages</th>
<th>Passage numbers at each stage</th>
<th>Lot</th>
<th>Laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>E4</td>
<td>E4</td>
<td>SI10036606</td>
<td>VIDRL, Australia</td>
</tr>
<tr>
<td>E11</td>
<td>E4/E7</td>
<td>L470</td>
<td>Seqirus, Australia</td>
</tr>
<tr>
<td>E13</td>
<td>E4/E7/E2</td>
<td>46590</td>
<td>NIBSC, UK</td>
</tr>
</tbody>
</table>

15. **LIABILITY AND LOSS**

In the event that this document is translated into another language, the English language version shall prevail in the event of any inconsistencies between the documents.

Unless expressly stated otherwise by NIBSC, NIBSC’s Standard Terms and Conditions for the Supply of Materials (available at http://www.nibsc.org/About_Us/Terms_and_Conditions.aspx or upon request by the Recipient) ("Conditions") apply to the exclusion of all other terms and are hereby incorporated into this document by reference. The Recipient’s attention is drawn in particular to the provisions of clause 11 of the Conditions.

16. **INFORMATION FOR CUSTOMS USE ONLY**

**Country of origin for customs purposes**: United Kingdom

* Defined as the country where the goods have been produced and/or sufficiently processed to be classed as originating from the country of supply, for example a change of state such as freeze-drying.

**Net weight**: 0.25g per ampoule

**Toxicity Statement**: Non-toxic

**Veterinary certificate or other statement** if applicable.

**Attached**: No

---

**Passage history of IVR-215 (H1N1)**

<table>
<thead>
<tr>
<th>Cumulative number of passages</th>
<th>Passage numbers at each stage</th>
<th>Lot</th>
<th>Laboratory</th>
</tr>
</thead>
<tbody>
<tr>
<td>E4</td>
<td>E4</td>
<td>SI10036606</td>
<td>VIDRL, Australia</td>
</tr>
<tr>
<td>E11</td>
<td>E4/E7</td>
<td>L470</td>
<td>Seqirus, Australia</td>
</tr>
<tr>
<td>E13</td>
<td>E4/E7/E2</td>
<td>46590</td>
<td>NIBSC, UK</td>
</tr>
</tbody>
</table>

* The HA titre of this virus using 0.7% turkey red blood cells is 1024. The infectious titre is unknown.

Sterility: No visible contamination was detected in a variety of media (tryptose soya broth, thioglycolate broth, Sabouraud's broth and blood agar plates) after 14 days incubation.

The HA and NA sequences of this virus are available at GISAID with the accession number EPI.ISL_17069062.
Derivation of IVR-215
A/Victoria/2570/2019 – like High Growth Reassortant

A/Victoria/2570/2019 (IVR-215) is a H1N1 high growth reassortant influenza virus.

PREPARATION
The preparation of A/Victoria/2570/2019 (IVR-215) high growth reassortant influenza virus was conducted in R&D Influenza Operations Technical Development Department at Seqirus.

The high yielding parent strain used was A/Texas/1/77 (IVR-6).

MATERIALS
The following materials of biological origin were used during the preparation of high growth reassortant IVR-215:

Virus Isolate:
The virus isolate was obtained from the WHO Collaborating Centre for Reference & Research on Influenza, Melbourne (WHO-CC).

Supply details are:
A/Victoria/2570/2019
WHO-CC Storage Lot number: SL10036606
Passages prior to receipt at WHO-CC: 0
Passages undertaken in WHO-CC: 4

Eggs:
Specific Pathogen Free (SPF) eggs were used for all passages at Seqirus.

Antiserum:
Trypsin-periodate treated sheep hyperimmune antiserum Lot# AS348, Sub-lot # 5009, raised against influenza virus A/Texas/1/77.

The antiserum was derived from sheep born and raised in Australia.

Note on Transmissible Spongiform Encephalopathies (TSEs):
Australia and New Zealand have been declared TSE free in accordance with OIE guidelines. Detailed information on Australia’s animal health status can be obtained from the following Animal Health Australia website link: https://www.ahah.org.au/what-we-do/disease-surveillance/oie-freedom-assurance-program/

The trypsin used is 10x solution of gamma irradiated porcine pancreatic trypsin; Invitrogen / Gibco Cat # 15090046, Lot No. 170500453.
### PASSAGE HISTORY:

<table>
<thead>
<tr>
<th>Passage</th>
<th>Description</th>
<th>HA titre</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mixed infection passage</strong></td>
<td>A/Victoria/2570/2019 wild type virus @10&lt;sup&gt;4&lt;/sup&gt; x A/Texas/1/77 (H3N2) @10&lt;sup&gt;-5&lt;/sup&gt;</td>
<td>469</td>
</tr>
<tr>
<td><strong>1&lt;sup&gt;st&lt;/sup&gt; Antiserum Passage</strong></td>
<td>Inoculum @ 10&lt;sup&gt;-3&lt;/sup&gt; with antiserum to A/Texas/1/77 (H3N2)</td>
<td>618</td>
</tr>
<tr>
<td><strong>2&lt;sup&gt;nd&lt;/sup&gt; Antiserum Passage</strong></td>
<td>Inoculum @ 10&lt;sup&gt;-4&lt;/sup&gt; with antiserum to A/Texas/1/77 (H3N2)</td>
<td>520</td>
</tr>
<tr>
<td><strong>1&lt;sup&gt;st&lt;/sup&gt; Limit Dilution Passage</strong></td>
<td>Inoculum @ 10&lt;sup&gt;-3&lt;/sup&gt;</td>
<td>663</td>
</tr>
<tr>
<td><strong>2&lt;sup&gt;nd&lt;/sup&gt; Limit Dilution Passage</strong></td>
<td>Inoculum @ 10&lt;sup&gt;-3&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td><strong>3&lt;sup&gt;rd&lt;/sup&gt; Limit Dilution Passage</strong></td>
<td>Inoculum @ 10&lt;sup&gt;-5&lt;/sup&gt;</td>
<td>1522</td>
</tr>
<tr>
<td><strong>4&lt;sup&gt;th&lt;/sup&gt; Limit Dilution Passage</strong></td>
<td>Inoculum @ 10&lt;sup&gt;-3&lt;/sup&gt;</td>
<td>1004</td>
</tr>
<tr>
<td><strong>5&lt;sup&gt;th&lt;/sup&gt; Limit Dilution Passage</strong></td>
<td>Inoculum @ 10&lt;sup&gt;-5&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Lot 420 (E4/D7)</td>
<td>IVR-215</td>
<td></td>
</tr>
</tbody>
</table>

* Virus sample diluted to 10<sup>-3</sup>, dilution was mixed with antiserum to A/Texas/1/77 (H3N2) and incubated for 1 hour at room temperature. Incubated virus/antiserum sample was serially diluted and inoculated into eggs.

Total number of passages post mixed infection = 6
Total number of passages since this virus was received from an approved laboratory = 7

HA titres were determined using fowl red blood cells at room temperature.
**TESTING OF A/VICTORIA/2570/2019 INFLUENZA VIRUS (IVR-215)**

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>Genotype (by real time RT-PCR)</td>
<td>1:5:2 (A/Texas/1/77 : A/Puerto Rico/8/34 : A/Victoria/2570/2019) Reassortant A/Texas/1/77 PB1 gene was detected A/Puerto Rico/8/1934 PB2, PA, NP, M and NS genes were detected. A/Victoria/2570/2019 (wild type virus) H1 and N1 genes were detected.</td>
</tr>
<tr>
<td>Gene</td>
<td>A/Texas/1/77</td>
</tr>
<tr>
<td>H3</td>
<td>X</td>
</tr>
<tr>
<td>N2</td>
<td>X</td>
</tr>
<tr>
<td>H1</td>
<td>NT</td>
</tr>
<tr>
<td>N1</td>
<td>NT</td>
</tr>
<tr>
<td>PB1</td>
<td>✓</td>
</tr>
<tr>
<td>PB2</td>
<td>NT</td>
</tr>
<tr>
<td>PA</td>
<td>NT</td>
</tr>
<tr>
<td>NP</td>
<td>NT</td>
</tr>
<tr>
<td>M</td>
<td>NT</td>
</tr>
<tr>
<td>NS</td>
<td>NT</td>
</tr>
</tbody>
</table>

✓ - positive by PCR   
X - negative by PCR   
NT – Not Tested

Disclaimer:
The material i.e. high growth reassortant virus IVR-215 and the information provided in this derivation report are provided on an “as is” basis and as such without any warranty or representation of any kind (expressed or implied) including, without limitation, of satisfactory quality or fitness for a particular purpose.

Prepared by:  
Lynda Allan  
Senior Scientist  
R&D Operations-Influenza, Seqirus

Date: 05/01/2020

Authorised by:  
Brad Dickason  
Manager, IVV Seed Facility  
R&D Operations-Influenza, Seqirus

Date: 05/01/2020